Toshio Kubo
- Oncology top 2%
- Lung Cancer Research Studies 33
- Colorectal Cancer Treatments and Studies 20
- Cancer Immunotherapy and Biomarkers 16
- HER2/EGFR in Cancer Research 12
- Peptidase Inhibition and Analysis 7
-
- Lung Cancer Treatments and Mutations 67
- Lung Cancer Diagnosis and Treatment 15
- Gastric Cancer Management and Outcomes 11
- Cancer Research top 10%
- Gastroenterology top 10%
- Surgery top 10%
- Co-authors
- Hidenobu WatanabeKatsuyuki KiuraEiki IchiharaKatsuyuki HottaTamaki ImaiKadoaki OhashiTakashi NinomiyaNagio Takigawa
- Journals
- Journal of Clinical Oncology (8 papers)SHILAP Revista de lepidopterología (1 paper)PLoS ONE (1 paper)
- Partner nations
- JapanUnited StatesSouth Korea
In The Last Decade
Toshio Kubo
119 papers receiving 2.0k citations
Peers
Comparison fields: 5 of 103
- Oncology 1.1k
- Pulmonary and Respiratory Medicine 1.2k
- Cancer Research 174
- Gastroenterology 50
- Surgery 394
Countries citing papers authored by Toshio Kubo
This map shows the geographic impact of Toshio Kubo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toshio Kubo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toshio Kubo more than expected).
Fields of papers citing papers by Toshio Kubo
This network shows the impact of papers produced by Toshio Kubo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toshio Kubo. The network helps show where Toshio Kubo may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Toshio Kubo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 4 | |
| 3 | 2023 | 2 | |
| 4 | 2023 | 2 | |
| 5 | 2023 | 3 | |
| 6 | 2023 | 1 | |
| 7 | 2021 | 13 | |
| 8 | 2021 | 1 | |
| 9 | 2020 | 6 | |
| 10 | 2017 | 12 | |
| 11 | 2017 | 123 | |
| 12 | Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines. | 2015 | 27 |
| 13 | 2013 | 54 | |
| 14 | 2012 | 38 | |
| 15 | 2011 | 17 | |
| 16 | 2009 | 17 | |
| 17 | Emergence of the EGFR T790M mutation in a lung adenocarcinoma cell line after vandetanib treatment | 2008 | 0 |
| 18 | Analysis of fractures in patients with rheumatoid arthritis | 2003 | 1 |
| 19 | 1973 | 16 | |
| 20 | 1971 | 50 |
About Toshio Kubo
Toshio Kubo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Applied Microbiology and Biotechnology, having authored 128 papers that have together received 2.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (67 papers), Lung Cancer Research Studies (33 papers), Colorectal Cancer Treatments and Studies (20 papers), Cancer Immunotherapy and Biomarkers (16 papers), Lung Cancer Diagnosis and Treatment (15 papers), HER2/EGFR in Cancer Research (12 papers), Gastric Cancer Management and Outcomes (11 papers) and Peptidase Inhibition and Analysis (7 papers). The work is most often cited by research in Oncology (1.1k citations), Pulmonary and Respiratory Medicine (1.2k citations) and Cancer Research (174 citations). Toshio Kubo has collaborated with scholars based in Japan, United States and South Korea. Frequent co-authors include Hidenobu Watanabe, Katsuyuki Kiura, Eiki Ichihara, Katsuyuki Hotta, Tamaki Imai, Kadoaki Ohashi, Takashi Ninomiya, Nagio Takigawa, Mitsune Tanimoto and Masahiro Tabata. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.